(Q36159287)

12 August 2017

1 reference

title

Prostanoids and phosphodiesterase inhibitors in experimental pulmonary hypertension (English)

1 reference

12 August 2017

0 references

Ralph Theo Schermuly

1

1 reference

12 August 2017

Hossein Ardeschir Ghofrani

series ordinal

2

1 reference

12 August 2017

Norbert Weissmann

series ordinal

3

1 reference

12 August 2017

publication date

1 January 2005

1 reference

Current Topics in Developmental Biology

12 August 2017

published in

1 reference

12 August 2017

volume

67

1 reference

12 August 2017

page(s)

251-284

1 reference

Effects of inhaled prostacyclin analogue on chronic hypoxic pulmonary hypertension

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

ZK 36-374, a stable analog of prostacyclin, prevents acute hypoxic pulmonary hypertension in the dog.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Prostanoid therapy for pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Evidence for the involvement of endothelial nitric oxide synthase from smooth muscle cells in the erectile function of the human corpus cavernosum

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Increased pulmonary prostacyclin synthesis in rats with chronic hypoxic pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Effects of sildenafil analogue UK 343-664 on a porcine model of acute pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Effects of inhaled nitric oxide and nebulized prostacyclin on hypoxic pulmonary vasoconstriction in anesthetized sheep.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Growth factor expression and effects of amrinone in monocrotaline-induced pulmonary hypertension in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Effects of nitric oxide after cardiac transplantation in the setting of recipient pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Effects of SCA40 on human isolated bronchus and human polymorphonuclear leukocytes: comparison with rolipram, SKF94120 and levcromakalim

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Characterization of a novel potent and specific inhibitor of type V phosphodiesterase

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Vasorelaxant effects of SCA40 (a phosphodiesterase III inhibitor) in pulmonary vascular preparations in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Low-dose PGI2 prevents monocrotaline-induced thromboxane production and lung injury

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Effects of PGE1 in experimental vasoconstrictive pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Additive effects of inhaled nitric oxide and intravenous milrinone in experimental pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Effects of amrinone and dobutamine on PGF2 alpha-induced pulmonary hypertension in dogs.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Nafazatrom (Bay g 6575) blunts canine hypoxic pulmonary vasoconstriction: evidence for a prostaglandin-mediated mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Arachidonic acid metabolites and an early stage of pulmonary hypertension in chronically hypoxic newborn pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Pulmonary hypertension in lambs with congenital diaphragmatic hernia: vasodilator prostaglandins, isoprenaline, and tolazoline

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Intravenous dipyridamole enhances the effects of inhaled nitric oxide and prevents rebound pulmonary hypertension in piglets

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Intermittent nitric oxide combined with intravenous dipyridamole in a piglet model of acute pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Nitric oxide generation and hypoxic vasoconstriction in buffer-perfused rabbit lungs

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3',5'-cyclic nucleotide phosphodiesterase

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Inhibition of lung phosphodiesterase improves responsiveness to inhaled nitric oxide in isolated-perfused lungs from rats challenged with endotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Cellular and molecular pathobiology of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Activation and pulmonary toxicity of pyrrolizidine alkaloids

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Selective pulmonary vasodilation induced by aerosolized zaprinast.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Acute and chronic effects of T-1032, a novel selective phosphodiesterase type 5 inhibitor, on monocrotaline-induced pulmonary hypertension in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

DA-8159, a potent cGMP phosphodiesterase inhibitor, attenuates monocrotaline-induced pulmonary hypertension in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

DA-8159, a new PDE5 inhibitor, attenuates the development of compensatory right ventricular hypertrophy in a rat model of pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Biochemical Studies on the Mechanism of Cardiotonic Activity of MDL 17,043

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Milrinone decreases both pulmonary arterial and venous resistances in the hypoxic dog.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Changes of sequestered leukocytes and platelets by inhalation prostaglandin E(1) in the pulmonary microvasculature of rats with monocrotaline-induced pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Suppressive effect of pulmonary hypertension and leukocyte activation by inhaled prostaglandin E1 in rats with monocrotaline-induced pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Inhibition of endogenous nitric oxide synthase potentiates nitrovasodilators in experimental pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Efficacy of inhaled prostanoids in experimental pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Characterization and effects of methyl-2- (4-aminophenyl)-1, 2-dihydro-1-oxo-7- (2-pyridinylmethoxy)-4-(3,4, 5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (P

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Prostacylin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin a gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Contribution of prostaglandins to the regulation of pulmonary vascular resistance in adult cats and dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Prostacyclin induces apoptosis of vascular smooth muscle cells by a cAMP-mediated inhibition of extracellular signal-regulated kinase activity and can counteract the mitogenic activity of endothelin-1 or basic fibroblast growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Effect of aerosolized prostacyclin and inhaled nitric oxide on experimental hypoxic pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Vasodilator therapy in microembolic porcine pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Protective effect of beraprost sodium, a stable prostacyclin analogue, in development of monocrotaline-induced pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

An assessment of the role of the inhibitory gamma subunit of the retinal cyclic GMP phosphodiesterase and its effect on the p42/p44 mitogen‐activated protein kinase pathway in animal and cellular models of pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

An in vitro study of corpus cavernosum and aorta from mice lacking the inducible nitric oxide synthase gene

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

E4021, a selective phosphodiesterase 5 inhibitor, potentiates the vasodilator effect of inhaled nitric oxide in isolated perfused rat lungs

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

PAF antagonists inhibit monocrotaline-induced lung injury and pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Influence of adenosine and prostacyclin on hypoxia-induced pulmonary hypertension in the anaesthetized pig.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Prostaglandin D2 inhibits hypoxic pulmonary vasoconstriction in neonatal lambs

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Vasodilator therapy in vasoconstrictor-induced pulmonary hypertension in sheep.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Suppressive effect of prostaglandin E1 on pulmonary hypertension induced by monocrotaline in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Low-dose Systemic Phosphodiesterase Inhibitors Amplify the Pulmonary Vasodilatory Response to Inhaled Prostacyclin in Experimental Pulmonary Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Zardaverine and aerosolised iloprost in a model of acute respiratory failure

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Prostacyclin production and mediation of adenylate cyclase activity in the pulmonary artery. Alterations after prolonged hypoxia in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Prostaglandin I2 supports blood flow to hypoxic alveoli in anesthetized dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

On-line measurement of nitric oxide generation in buffer-perfused rabbit lungs

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Site of hypoxic pulmonary vasoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Gene transfer of human prostacyclin synthase into the liver is effective for the treatment of pulmonary hypertension in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Type V phosphodiesterase inhibition modulates endogenous immunoreactivities of endothelin-1 and endothelial nitric oxide synthase in pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Effects of milrinone on lung water content in dogs with acute pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Endothelin-A-receptor antagonist and oral prostacyclin analog are comparably effective in ameliorating pulmonary hypertension and right ventricular hypertrophy in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

A combination of oral endothelin-A receptor antagonist and oral prostacyclin analogue is superior to each drug alone in ameliorating pulmonary hypertension in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Combination of inhaled nitric oxide with i.v. nitroglycerin or with a prostacyclin analogue in the treatment of experimental pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Observations on the Pulmonary Arterial Blood Pressure in the Cat

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Prostaglandin E1 inhibits the pulmonary vascular pressor response to hypoxia and prostaglandin F2α

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Downregulation of hypoxic vasoconstriction by chronic hypoxia in rabbits: effects of nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Nitric oxide (NO)-dependent but not NO-independent guanylate cyclase activation attenuates hypoxic vasoconstriction in rabbit lungs.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Methylxanthine inhibitors of phosphodiesterases

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

PGI2 aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Prostacyclin Analogues Differentially Inhibit Growth of Distal and Proximal Human Pulmonary Artery Smooth Muscle Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Mechanisms and pathology of monocrotaline pulmonary toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Orally administered beraprost sodium inhibits pulmonary hypertension induced by monocrotaline in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Sildenafil inhibits hypoxia-induced pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Effects of inhaled prostacyclin as compared with inhaled nitric oxide on right ventricular performance in hypoxic pulmonary vasoconstriction.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin, and nifedipine in experimental porcine pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0070-2153%2805%2967008-1

7 January 2021

10.1016/S0070-2153(05)67008-1

Identifiers

DOI

1 reference

12 August 2017

1 reference